January 22-24, 2019

San Francisco, CA

View Event Guide


Challenges, Insights, and Future Directions for
Experimental Models in Cancer Immunotherapy

Tuesday, January 22


Understanding tumor placement, immune composition, response to treatment, and molecular characterization for the model of interest can be invaluable when designing the most appropriate study for your research goals. However, major issues remain not just in selecting and optimizing models and tools for cancer immunotherapy research but in selecting who to work with and when.

Discussions in this session will centre on:

• The range of current IO models available amongst their  strengths and weaknesses
• Mouse syngeneic models, their genetic backgrounds and use in  IO for mono or combination  therapy
• How to identify, select and work with model developers and  CRO’s available

Your workshop leader:


Shiva Kazerounian
Principal Scientist, In Vivo Pharmacology Lead
Berg Pharma

Utilize Humanized Mice for Your Immuno-Oncology Preclinical Research For Increased Translational Success

Tuesday, January 22


Understanding the interactions between human immune cells and tumors is paramount when devising treatment strategies that prevent tumor evasion of immune cells and improve cytotoxic responses.

Discussions in this session will centre on:

  • Patient derived xenograft (PDX) mouse models recapitulate disease progression and respond to standard of care (SoC) and experimental therapies
  • Specialized, immunodeficient mouse models are efficiently reconstituted with functional human immune cells
  • Tumor-bearing, humanized NSG and NSG-SGM3 (Onco-Hu) mice are a new and valuable tool for immuno-oncology research

Your workshop leader:


James Keck
Senior Director, In Vivo Pharmacology & Clinical Lab Services
The Jackson Laboratory

Organoids and the Transgenic Manipulation of Human Tumor Models

Tuesday, January 22


Rapid advances in therapeutic areas like cancer immunotherapy, has created a need for translational strategies to more effectively guide indication selection, understand mechanisms of resistance and identify biomarkers of response. 3D organoids have presented huge opportunities to bridge the in vitro and in vivo gap. Providing insights, beyond basic descriptors at the cellular level, these models are offering new insights signaling, microenvironments, and cell-type specific behavior.  This workshop this session will look to explore the technical advances in designing these models. It will cover how organoid systems are being further adapted towards applications within the basic and pharmaceutical setting through the use of transgenic and other editing technologies as well as strategies for overcoming remaining issues to use.

Discussions in this session will centre on:

  • How to develop flexible strategies with organoid cultures to maximize predictability and translatability of early discoveries
  • Assessing the translational capability and remaining limitations of organoid cultures
  • Applications of organoids in understanding of disease biology, mechanisms to disease and opening up new avenues for the path to target
  • Cross comparative analyses of data generated in CRISPR/transgenically  edited organoid systems to in vivo systems

Your workshop leader:


Joshua Breunig
Assistant Professor, Board of Governors Regenerative Medicine Institute

Cedars-Sinai Medical Center, UCLAatory